Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 71 of 5804
-
Could a weekly shot stop diabetes after pregnancy diabetes?
Prevention Recruiting nowGestational diabetes (GDM) is an important contributor to the increasing prevalence of type 2 diabetes (T2DM). Women with glucose intolerance in early postpartum are a particularly high-risk group with about 50% who will develop T2DM within 5 years after the delivery. Moreover, w…
Phase: PHASE3 • Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Prevention
Last updated Jul 09, 2026 00:00 UTC
-
New immunotherapy cocktail aims to fight untreatable liver cancer
Disease control OngoingThe purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic HCC. Pe…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
One-Time gene injection aims to restore sight in rare eye disease
Disease control OngoingThe purpose of the study is to evaluate the efficacy and safety of LX101 in subjects with biallelic RPE65 mutation-associated inherited retinal dystrophy. This is an open-label, multicenter, randomized controlled Phase III clinical trial. Subjects were randomly assigned in a 1:1 …
Phase: PHASE3 • Sponsor: Innostellar Biotherapeutics Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New RSV shot shows promise in protecting infants from severe lung infections
Prevention CompletedThe purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), neutralizing antibody and antidrug antibody (ADA) response for TNM001 in infants entering their first RSV season.
Phase: PHASE2, PHASE3 • Sponsor: Zhuhai Trinomab Pharmaceutical Co., Ltd. • Aim: Prevention
Last updated Jun 27, 2026 09:10 UTC
-
New targeted combo aims to stall HER2+ breast cancer
Disease control Recruiting nowThis study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with p…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers with a specific gene mutation
Disease control Recruiting nowThis study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.
Phase: PHASE1 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Experimental brain cancer cocktail shows promise in early trial
Disease control Recruiting nowThe purpose of this research study is to determine the safety and efficacy of administering a single intracerebral (within the brain) dose of investigational compounds called D2C7-immunotoxin (IT) and 2141-V11 in residual disease (within tumor margins) after surgery, followed by …
Phase: PHASE1, PHASE2 • Sponsor: Darell Bigner • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Gene therapy breakthrough offers hope for rare heart disease
Disease control Recruiting nowThis is a single arm Phase 2 trial to evaluate the efficacy and safety of RP-A501, a recombinant adeno-associated virus serotype 9 (AAV9) containing the human lysosome-associated membrane protein 2 isoform B (LAMP2B) transgene, in male patients with Danon Disease.
Phase: PHASE2 • Sponsor: Rocket Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Double-Barreled attack: stem cell transplant plus CAR-T shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis is a single center, prospective cohort study to to evaluate the efficacy and safety of autologous hematopoietic stem cell transplantation(ASCT) bridging chimeric antigen receptor T (CART) cell therapy in the treatment of relapsed/refractory B-cell non-Hodgkin's lymphoma.
Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug combo aims to beat leukemia in phase 3 trial
Disease control Recruiting nowA global multicenter, open-label, randomized and registrational Phase 3 study to evaluate efficacy and safety of olverembatinib combined with chemotherapy versus investigator's choice of tyrosine kinase inhibitor (TKI) combined with chemotherapy in subjects with newly-diagnosed P…
Phase: PHASE3 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Gene therapy infused directly into brain aims to halt rare dementia
Disease control Recruiting nowThe goal of this clinical study is to learn about an investigational gene therapy product called AVB-101, which is designed to treat a disease called Frontotemporal Dementia with Progranulin Mutations (FTD-GRN). FTD-GRN is an early-onset form of dementia, a progressive brain diso…
Phase: PHASE1, PHASE2 • Sponsor: AviadoBio Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Gene therapy slows vision loss in stargardt disease trial
Disease control OngoingPhase 2/3 Pivotal Confirmatory Clinical Trial is a randomized, outcome assessor-masked, multicenter study, that will enroll fifty-one (51) subjects. Subjects will be enrolled in a 2:1 ratio to either the treatment group (n=34 subjects) or to an untreated control group (n=17 subje…
Phase: PHASE2, PHASE3 • Sponsor: Ocugen • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New Self-Test could slash cervical cancer rates in developing nations
Prevention Recruiting nowIn May 2018, the World Health Organization (WHO) launched a strategy to eliminate cervical cancer. While this strategy seeks to achieve coverage of 70% in disease testing and 90% in treatment by 2030, it is estimated that these goals will not be achieved by most low- and middle- …
Sponsor: Atila Biosystems Inc. • Aim: Prevention
Last updated Jun 27, 2026 07:58 UTC
-
Could a short course of antiviral drugs stop hepatitis b passing from mother to child?
Disease control Recruiting nowPregnant women with HBeAg-positive viral hepatitis b or high viral load will receive Tenofovir disoproxil fumarate (TDF) from the 28th week of amenorrhoea until 6 weeks after delivery. Their newborns will receive the hepatitis B vaccine, starting with one dose at birth and follow…
Phase: PHASE4 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Gene therapy trial aims to save sight in boys and men with rare retinal disease
Disease control Recruiting nowThis study will evaluate the safety and efficacy of ATSN-201 in subjects ≥ 6 years of age with RS1-associated X-linked retinoschisis (XLRS).
Phase: PHASE3 • Sponsor: Atsena Therapeutics Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Zapping lung nerves could ease heart Failure-Related high blood pressure
Disease control OngoingIt's a phase III, prospective, multicenter, randomized controlled trial to evaluate the safety and efficacy of the pulmonary artery denervation (PADN) for heart failure (HF) patients diagnosed with pulmonary hypertension associate with left heart disease (PH-LHD) by right heart c…
Phase: PHASE3 • Sponsor: Pulnovo Medical (Wuxi) Co., Ltd. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New breast cancer pill combo shows promise in Late-Stage trial
Disease control OngoingThe purpose of this study is to understand the safety and effects of the study medicine vepdegestrant (ARV-471/PF-07850327) given together with palbociclib in advanced breast cancer. In particular, the study will compare the combination of vepdegestrant plus palbociclib to standa…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
One-Time gene therapy could free PKU patients from strict diet
Disease control OngoingThis is a single group Phase 1/Phase 2, 1-arm, open-label study with SAR444836, an adeno-associated virus (AAV) vector-mediated gene transfer of human phenylalanine hydroxylase (PAH), for the treatment of adult participants with phenylketonuria (PKU) on a chronic, stable diet. Th…
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New short-course malaria cure could save thousands
⭐️ CURE ⭐️ CompletedThe proportion of malaria that is the Plasmodium vivax species is increasing in Indonesia. Reducing vivax malaria will require innovative solutions to cure both the blood and liver stages of the disease. This study will evaluate of the feasibility of implementing point-of-care gl…
Phase: NA • Sponsor: Menzies School of Health Research • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 08:11 UTC
-
Engineered immune cells take on tough lymphoma
Disease control Recruiting nowThis is a multi-center, phase I/II study to determine the safety and efficacy of TC011(CD19 Targeted CAR-T) in adult patients with relapsed or refractory large B-cell non -hodgkin lymphoma.
Phase: PHASE1, PHASE2 • Sponsor: TICAROS Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC